Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Headquartered in Vancouver, Canada, BioNxt Solutions Inc., established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery systems, including transdermal patches and oral dissolvable films, specifically for neurological medications. It also advances psychedelic medicine applications to treat various mental health conditions such as depression, anxiety, addiction, and trauma-related stress disorder. Furthermore, BioNxt is engaged in creating point-of-care diagnostics, comprising rapid tests and biosensor screening tools, aimed at early disease detection, improved treatment efficacy, and enhanced disease management. This diagnostic portfolio features a COVID-19 PCR kit, alongside oral biosensors for peri-implantitis, H1N1 (swine flu), and H5N1 (avian flu). Complementing its development efforts, the company provides analytical testing and consulting services, and is involved in pathogen and oral health diagnostics, thin film drug formulation, and the production and formulation of psychedelic pharmaceuticals. The company adopted its current name in November 2022, having previously been known as XPhyto Therapeutics Corp.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.